Biology of Blood and Marrow Transplantation
Volume 15, Issue 4 , Pages 512-516 , April 2009

Imipenem/Cilastatin with or without Glycopeptide as Initial Antibiotic Therapy for Recipients of Autologous Stem Cell Transplantation: Results of a Spanish Multicenter Study

Received 11 October 2008 ,Accepted 22 December 2008.

References 

  1. Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant. 1996;18:265–271
  2. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997;19:143–147
  3. Weaver CH, Schwartzberg LS, Hainsworth J, et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant. 1997;19:671–678
  4. Salazar R, Sola C, Maroto P, et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:27–33
  5. Reich G, Mapara MY, Reichardt P, Dörken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001;27:525–529
  6. Gil L, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection. 2007;35:421–427
  7. Reich G, Cornely O, Sandherr M, et al. Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicenter trial. Br J Haematol. 2005;130:265–270
  8. Koya R, Andersen J, Fernandez H, et al. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21:923–926
  9. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis. 1999;29:503–507
  10. Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother. 2000;45:843–849
  11. Pizzo PA, Armstrong D, Bodey G, De Pauw B, Feld R, Glauser M. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis. 1990;161:397–401
  12. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;15(Suppl. 1):206–215
  13. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropaenic patients with unexplained fever. Clin Infect Dis. 1997;25:573
  14. National Committee for Clinical Laboratory Standard. Performance Standard for Antimicrobial Susceptibility Testing. Villanova, PA: NCCLS; 1994;
  15. World Health Organization . Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979;
  16. Dixon WJ, Brown MB, Engelman L, Jeinrich RI. BMDP Statistical Analysis Software. Berkeley, CA: University of California; 1994;
  17. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Amtimicrob Agents Chemother. 1996;18:25–31
  18. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14:1202–1207
  19. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002;34:1524–1549
  20. Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia. Toward a more targeted antibiotic strategy. Clin Infect Dis. 2003;36:149–158
  21. Raad , Abi-Said D, Rolston KV, Karl CL, Bodey GP. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?. Cancer. 1998;82:2449–2458
  22. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67:1027–1052
  23. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001;33:1295–1301
  24. Feld R, DePauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized double-blind trial. J Clin Oncol. 2000;18:3690–3698
  25. Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropaenic cancer patients. Clin Microbiol Infect. 2006;12:212–216

 Financial disclosure: See Acknowledgments on page 515.

PII: S1083-8791(08)01137-3

doi: 10.1016/j.bbmt.2008.12.505

Biology of Blood and Marrow Transplantation
Volume 15, Issue 4 , Pages 512-516 , April 2009

Article Tools